Epidemiology update for hepatitis C virus and hepatitis B virus in end‐stage renal disease in France

Bagnis, Corinne Isnard; Couchoud, Cécile; Bowens, Marc; Sarraj, Ayman; Deray, Gilbert; Tourret, Jérôme; Cacoub, Patrice; Montcel, Sophie Tezenas du

doi:10.1111/liv.13367

Cited by 23 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the introduction of serological assays for the detection of HCV infection, several multi‐center surveys exist, mostly based on serologic detection of HCV infection (Table ). On the basis of this body of data, prevalence rates have been shown to range between 1.4% and 28.3% …”

Section: Hcv and Dialysis‐dependent Ckd: Epidemiologymentioning

confidence: 99%

The epidemiology of HCV infection in patients with advanced CKD/ESRD: A global perspective

Fabrizi

2018

Seminars in Dialysis

View full text Add to dashboard Cite

Liver disease in patients with chronic kidney disease (CKD) is most commonly due to hepatitis C virus (HCV) and contributes to increased rates of mortality. Among the pre-dialysis population, the estimated prevalence of anti-HCV positivity is based on few, limited-size studies. In hemodialysis patients however, HCV remains very prevalent despite large declines in seropositivity rates in dialysis facilities in developed countries after preventive measures were adopted in the 1990s. Recent surveys indicate that the HCV seropositivity prevalence ranges from 1.4%-28.3%, and 4.7%-41.9%, among maintenance dialysis patients in developed and developing countries respectively. Although the full extent of dialysis unit-associated HCV transmission is unknown, outbreaks continue to occur, regardless of health system infrastucture. According to US Centers for Disease Control data, over 50% of health care-associated HCVoutbreaks reported from 2008 to 2015 occurred within dialysis facilities. Strict adherence to infection control procedures and routine serologic screening plays a pivotal role in preventing transmission of HCV within hemodialysis units, even in the setting of low HCV prevalence. With the advent of directly acting antivirals, cure of HCV-infected patients on maintenance hemodialysis will help reduce transmission within units and further lower the frequency of HCV infection.

show abstract

Section: Hcv and Dialysis‐dependent Ckd: Epidemiologymentioning

confidence: 99%

The epidemiology of HCV infection in patients with advanced CKD/ESRD: A global perspective

Fabrizi

2018

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…The frequency of cirrhosis in dialysis patients is an overlooked topic which was confounded in the 1980s and 1990s by the spread of hepatitis B in dialysis units. This was successfully counteracted in Western countries by drastic hygiene measures, vaccination and serotherapy of patients, and thereafter by hepatitis C virus infection, which has only very recently been managed in ESRD patients with new direct anti-viral agents leading to viral eradication [[39], [40], [41]]. Moreover, all forms of cirrhosis (related to haemosiderosis, alcoholic liver disease, viral hepatitis, NASH, and genetic haemochromatosis) generally take many years to fully develop: therefore, the short lifespan of many dialysis patients may also account for the scarcity of diagnosed cirrhosis in ESRD patients on dialysis.…”

Section: Discussionmentioning

confidence: 99%

Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study

et al. 2019

View full text Add to dashboard Cite

BackgroundNonalcoholic fatty liver disease (NAFLD) is a spectrum of diseases including steatosis, nonalcoholic steatohepatitis (NASH), cirrhosis, and end-stage liver failure. Hepatic iron accumulation has been linked to hepatic fibrosis severity in NASH and NAFLD. Iron overload induced by parenteral (IV) iron therapy is a potential clinical problem in dialysis patients. We analyzed the hypothetical triggering and aggravating role of iron on NAFLD in patients on dialysis.MethodsLiver iron concentration (LIC) and hepatic proton density fat fraction (PDFF) were analyzed prospectively in 68 dialysis patients by magnetic resonance imaging (MRI). Follow up of LIC and PDFF was performed in 17 dialysis patients during iron therapy.FindingsPDFF differed significantly among dialysis patients classified according to LIC: patients with moderate or severe iron overload had increased fat fraction (PDFF: 7.9% (0.5–14.8%)) when compared to those with normal LIC (PDFF: 5% (0.27–11%)) or mild iron overload (PDFF: 5% (0.30–11.6%); P = 0.0049). PDFF correlated with LIC, and ferritin and body mass index. In seven patients monitored during IV iron therapy, LIC and PDFF increased concomitantly (PDFF: initial 2.5%, final 8%, P = 0.0156; LIC: initial 20 μmol/g, final 160 μmol/g: P = 0.0156), whereas in ten patients with iron overload, PDFF decreased after IV iron withdrawal or major dose reduction (initial: 8%, final: 4%; P = 0.0098) in parallel with LIC (initial: 195 μmol/g, final: 45 μmol/g; P = 0.002).InterpretationLiver iron load influences hepatic fat fraction in dialysis patients. Iron overload induced by iron therapy may aggravate or trigger NAFLD in dialysis patients.Trial registration number (ISRCTN)80100088.

show abstract

“…The link between dialysis units and HBV and HCV is well known [ 4 ], yet recent years have seen significant improvements, brought about mainly by the advent of highly reliable diagnosis of these infections in renal affected patients receiving dialysis, vaccination in the case of HBV, and effective viral infection treatment, achieving partial response in HBV and complete and sustained response in HCV patients. These developments have allowed a major shift in this interrelationship.…”

Section: Hepatitis Virus In the Dialysis Populationmentioning

confidence: 99%

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

D’Marco

Puchades

Serra

et al. 2021

IJERPH

View full text Add to dashboard Cite

Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with vaccination in the case of HBV and effective viral infection treatment for HCV. In this sense, a universal SARS-CoV-2 screening and contact precaution appear to be effective in preventing further transmission. Finally, regarding the progress, an international consensus with updated protocols that prioritize between old and new indicators would seem a reasonable tool to address these unexpended changes for the nephrology community.

show abstract

Epidemiology update for hepatitis C virus and hepatitis B virus in end‐stage renal disease in France

Abstract: Our data highlight the need for HCV therapy for more than 1000 end-stage renal disease patients in France, sustained systematic immunization campaigns (HBV) and underlines the persistence of HBV/HCV new hand-borne nosocomial cases.

Cited by 23 publications

References 22 publications

The epidemiology of HCV infection in patients with advanced CKD/ESRD: A global perspective

The epidemiology of HCV infection in patients with advanced CKD/ESRD: A global perspective

Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

Contact Info

Product

Resources

About